Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Pharmaceuticals

Delayed Nasdaq 12:57:08 2024-03-28 pm EDT 5-day change 1st Jan Change
0.6242 USD +6.37% Intraday chart for Evoke Pharma, Inc. +5.80% -40.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024 CI
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024 CI
Transcript : Evoke Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024
Evoke Pharma, Inc. Provides Earnings Guidance for 2024 CI
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Evoke Pharma Prices Underwritten Public Offering MT
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book MT
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI CI
Evoke Pharma, Inc. Enters into Sixth Amendment to Lease with SB Corporate Centre III-IV, LLC CI
Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI CI
Evoke Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Evoke Pharma, Inc. - Special Call
North American Morning Briefing : Retail Sales, -2- DJ
Evoke Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Evoke Pharma Patent Added To US FDA Orange Book Of Drug Products MT
Evoke Pharma, Inc. Announces United States Patent and Trademark Office Issues US Patent No. 11,628,150 Under the Title Nasal Formulations of Metoclopramide CI
Evoke Pharma Says US Patent and Trademark Office Grants Formulation Patent Covering GIMOTI Nasal Spray MT
Evoke Pharma's Q4 Loss per Share Narrows, Revenue Gains MT
Evoke Pharma, Inc. Provides Revenue Guidance for 2023 CI
Transcript : Evoke Pharma, Inc., Q4 2022 Earnings Call, Mar 21, 2023
Earnings Flash (EVOK) EVOKE PHARMA Posts Q4 Revenue $796,000 MT
North American Morning Briefing : Stock Futures -2- DJ
Evoke Pharma, Inc. Auditor Raises 'Going Concern' Doubt CI
Evoke Pharma, Inc. Announces Executive Changes CI
Chart Evoke Pharma, Inc.
More charts
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.5868 USD
Average target price
7 USD
Spread / Average Target
+1,092.91%
Consensus
  1. Stock
  2. Equities
  3. Stock Evoke Pharma, Inc. - Nasdaq
  4. News Evoke Pharma, Inc.
  5. Insider Trends: Evoke Pharma Insider Disposition Interrupting 90-Day Buy Trend